Table 1.
Published results of clinical trials of bispecific antibodies in AML.
| Target | Agent | Phase | Disease | Outcome | NCT ID | |
|---|---|---|---|---|---|---|
| BiTE | CD33 × CD3 | AMG330 | I | R/R AML | CR+CRi:19% | NCT02520427 |
| CRS:67% | ||||||
| CD33 × CD3 | AMV564 | I | R/R AML | CR+CRi:66.7% | NCT03144245 | |
| CRS:5.7% | ||||||
| CD33 × CD3HLE | AMG673 | I | R/R AML | Blast reduction:44% | NCT03224819 | |
| CRS:50% | ||||||
| CD123 × CD3 | APVO436 | I | R/R AML | Blast reduction: 7% | NCT03647800 | |
| CRS:18% | ||||||
| CD123 × CD3 | XmAb14045 | I | R/R AML | CR+CRi:14% | NCT02730312 | |
| (Vibecotamab) | CRS:59% | |||||
| DART | CD123 × CD3 | Flotetuzumab | I/II | R/R AML | CR/CRi:27% | NCT02152956 |
| CRS13% | ||||||
| TRiKE | CD33 × CD16 × IL15 | 1-GBT-3550 | I | PIF R/R AML | SD:50%; POD:25% | NCT03214666 |
| No toxicity |
BiTE: bispecific T-cell engager; DART: Dual-affinity Re-Targeting Molecules (BiTE); HLE: half-life extended; TRiKE: tri-specific killer engager; R/R: relapsed/refractory; CR: complete remission; CRi: complete remission with incomplete hematologic recovery; SD: stable disease: POD: progression of disease; PIF: primary induction failure; CRS: cytokine-release syndrome.